EDX Medical Group

CEO, Dr Mike Hudson, provides an insight to the progress of EDX Medical in an interview with the StockBox investor platform at the recent Aquis Exchange Showcase event. Mike gives an update on the company's continued growth and development of digital diagnostic solutions to help improve treatment of cancer, cardiovascular disease and infectious diseases. https://buff.ly/3Cu48nW #EDX Medical #AQSE www.edxmedical.com

With Movember in full flight, there is no better time to highlight the issue of testicular cancer. EDX Medical applauds the Movember movement’s efforts to raise awareness of the disease and treatment options. And the annual initiative coincides with EDX Medical reaching agreement with mir|detect to distribute an innovative testicular cancer diagnostic test in the UK and Nordic markets. Read more: https://lnkd.in/emA568kc #EDXMedical #HealthcareInnovation #MedicalAdvancements #diagnostics #cancerdiagnostics

EDX Medical Group's CEO, Dr Mike Hudson, will be delivering a presentation at the Hardman & Co Investor Forum later this afternoon. Following the recent UK budget, this forum serves as a key opportunity for investors and industry professionals to learn about innovations and emerging trends, as well as discussing the implications for growth in the healthcare sector and elsewhere in the economy. To join the conversation and ask your questions during a live Q&A, register here to secure your place: https://lnkd.in/eSpD6EbE

EDX Medical Group plc has signed an exclusive distribution agreement with mir|detect GmbH ("mir|detect") to distribute its M371 testicular cancer diagnostic test in the UK and Nordic markets.   The M371-Test is a simple blood test that enables highly accurate detection of critical biomarkers of testicular cancer in its early stages, the most common form of cancer among young men. More than 20,000 new cases are diagnosed each year in Europe. The test provides a highly reliable and cost-effective test solution which detects recurrences during the follow-up monitoring of patients with 100% sensitivity. In the UK alone, there are 50,000 survivors of testicular cancer who may benefit from post-diagnosis monitoring.   The agreement between EDX Medical and mir|detect covers the UK, Sweden, Finland, Norway and Denmark.   Sir Christopher Evans, Professor, founder of EDX Medical Group plc, commented: "We are delighted to be partnering with mir|detect to increase patient's access to this marvellous test which is clearly outstanding when compared with previous tests for this type of cancer. This test is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions." Dr Mike Hudson, CEO, EDX Medical Group plc, said: "We are very pleased to be appointed as the exclusive distributor of the M371-Test in several countries, which is an excellent fit with our range of diagnostics which enable healthcare professionals to personalise and optimise treatment decisions for all patients. EDX Medical expects to continue to work with mir|detect in future to further refine and develop the test and associated services."   Dr Nina Winter, CEO, mir|detect commented: "The M371-Test provides faster and more reliable diagnosis of testicular germ cell tumours. It is minimally invasive, patient friendly and has a very high and reliable detection of recurrence in patients. We are delighted to have established our new relationship with EDX Medical." #EDXMedical #HealthcareInnovation #MedicalAdvancements #diagnostics #cancerdiagnostics

We are delighted to announce EDX Medical Group will be presenting at the Hardman & Co Investor Forum on Thursday, 14th November. Join us to explore market opportunities following the recent budget and discuss what this means for growth companies and investors in the healthcare sector. Don’t miss the chance to gain valuable insights and engage in a live Q&A. Secure your spot today and submit your questions - https://lnkd.in/eQuJmCMa #investments #capitalmarkets #ukbudget

EDX Medical Group will be presenting at the Aquis Showcase Event on Tuesday, 12 November 2024 at the Royal College of Surgeons, the View, 6th floor 38–43 Lincoln's Inn Fields London WC2A 3PE. There will be a presentation from the Company to delegates between 1pm and 1.30pm and senior management from the Company will be available throughout the day to engage with investors. The Aquis Showcase Event is a one-day event with companies presenting and competing in an investment contest, to be judged by a panel of experts and those in attendance. EDX Medical investors are encouraged to attend the event and watch the presentation. For further information on the even and to purchase tickets, please visit the event website here: https://lnkd.in/gKpA5c7a #Aquisshowcase #Aquisstockexchange

EDX Medical’s chief commercial officer, Eric Vick, and Erik Jensen, regional manager UK & Nordics, caught up with Marcel van Lier from our precision oncology partners, Caris Life Sciences, at ESMO. EDX Medical is delighted to be distributing Caris’ portfolio of advanced and comprehensive molecular profiling services in the UK. Digital diagnostics have been highlighted throughout #ESMO24 and it's clear this is an increasingly important part of patient care. #ESMO24

EDX Medical Group has announced the appointment of Eric Vick as Chief Commercial Officer. The appointment follows the successful completion of several key commercial agreements which enable the Company to develop and market a range of innovative diagnostic products and services in the UK and key European countries. Eric has worked in the life sciences sector for more than 25 years, building and leading commercial business units for companies from start-ups to global leaders including GSK, Novartis, ViroPharma, Bio Products Laboratory, Ethypharm and Rosemont Pharma. As a commercial leader, Eric has a proven track record of delivering sales and profit growth by launching new products, geographic expansion, business development, and M&A. Having started his career in the US, he has expanded his remit, experience and business network across Europe, Latin America, the Middle East, Africa, and Asia-Pacific. Read more:- https://lnkd.in/eKUFWt3u

Cambridge life science company EDX Medical Group plc, part of the Sir Chris Evans stable, has signed a distribution agreement with Caris Life Sciences® , a leading US-based nextgen AI TechBio and precision medicine company. EDX Medical and Caris will collaborate on a mutually exclusive basis in the UK and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use. Caris’ solid tumour and liquid (blood) biopsy molecular profiling services, as well as AI solutions, will be available exclusively via EDX Medical immediately in the UK, Sweden, Denmark, Norway and Finland, with additional regions and products to follow. EDX Medical CEO Dr Mike Hudson said: “We are proud to have been selected by Caris to play a key role in jointly bringing these incredibly useful cancer tumour profiling services to the UK and key areas of Europe.” Dr David Spetzler, Caris Life Sciences President, added: “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.” Based at Cambridge Science Park, EDX develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases. Sir Christopher Evans, Professor, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of illness for patients. “The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.” Full article – https://lnkd.in/e2kWnbMq

EDX Medical Group has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation AI TechBio and precision medicine company. Under the agreement, EDX Medical and Caris will work together on a mutually exclusive basis in the United Kingdom (UK) and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use. Professor Sir Chris Evans, OBE, founder of EDX Medical, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of cancer for patients. “The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.” Read more:- https://lnkd.in/e_URApEP #EDXMedical hashtag #HealthcareInnovation hashtag #PointOfCareTesting hashtag #MedicalAdvancements hashtag #diagnostics hashtag #cancerdiagnostics hashtag #cancer